Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 6/20 | 1.00 |
| ▸ | BACE1 | P56817 | 4/20 | 1.00 |
| ▸ | PTPN1 | P18031 | 2/20 | 1.00 |
| ▸ | MAOB | P27338 | 6/20 | 0.73 |
| ▸ | PTGES | O14684 | 1/20 | 0.69 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.69 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.69 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.69 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.65 |
| ▸ | TRPM7 | Q96QT4 | 1/20 | 0.65 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.65 |
| ▸ | CNR2 | P34972 | 1/20 | 0.64 |
| ▸ | CTSL | P07711 | 1/20 | 0.56 |
| ▸ | MGAM | O43451 | 1/20 | 0.55 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Grifolic Acid SCHEMBL12180037 | 1.00 | APP (1.00) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL15363875 | 0.99 | APP (0.97) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL15363878 | 0.99 | APP (0.97) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL29770918 | 0.99 | APP (0.97) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL21710543 | 0.99 | APP (0.97) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL2725955 | 0.90 | APP (0.81) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL23523338 | 0.86 | BACE1 (0.76) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL23523334 | 0.86 | BACE1 (0.76) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL12180036 | 0.86 | APP (0.75) | APPBACE1PTPN1MAOBPTGES | |
| SCHEMBL23523351 | 0.85 | APP (0.74) | APPBACE1PTPN1MAOBPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230095374-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | GLIAPHARM SA (CH) | 2023-03-30 | — | — | US | disclosed |
| US-20200405676-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | GLIAPHARM SA (CH) | 2020-12-31 | — | — | US | disclosed |
| EP-3681488-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | Société des Produits Nestlé S.A. (CH) | 2020-07-22 | — | — | EP | disclosed |
| CN-111050759-A | Heteroterpene compounds for the prevention and treatment of neurological disorders | 雀巢产品有限公司 | 2020-04-21 | — | — | CN | disclosed |
| WO-2019053159-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | NESTEC S.A. (CH) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200405676-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | NLN, SLC6A13, SLC6A11 | APP 68/4885BACE1 373/4885PTPN1 4605/4885 |
| US-20230095374-A1 | MEROTERPENOID COMPOUNDS FOR USE IN THE PREVENTION AND TREATMENT OF A NEUROLOGICAL DISORDER | NLN, SLC6A13, SLC6A11 | APP 68/4885BACE1 373/4885PTPN1 4605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.